Assessment and mitigation of bias in influenza and COVID-19 vaccine effectiveness analyses — IVY Network, September 1, 2022–March 30, 2023
Lewis N, Harker E, Leis A, Zhu Y, Talbot H, Grijalva C, Halasa N, Chappell J, Johnson C, Rice T, Casey J, Lauring A, Gaglani M, Ghamande S, Columbus C, Steingrub J, Shapiro N, Duggal A, Felzer J, Prekker M, Peltan I, Brown S, Hager D, Gong M, Mohamed A, Exline M, Khan A, Wilson J, Mosier J, Qadir N, Chang S, Ginde A, Mohr N, Mallow C, Harris E, Johnson N, Srinivasan V, Gibbs K, Kwon J, Vaughn I, Ramesh M, Safdar B, DeCuir J, Surie D, Dawood F, Ellington S, Self W, Martin E. Assessment and mitigation of bias in influenza and COVID-19 vaccine effectiveness analyses — IVY Network, September 1, 2022–March 30, 2023. Vaccine 2024, 43: 126492. PMID: 39515195, DOI: 10.1016/j.vaccine.2024.126492.Peer-Reviewed Original ResearchCo-circulating virusesRespiratory syncytial virusCOVID-19-associated hospitalizationVaccine effectivenessControl groupRespiratory pathogensInfluenza-associated hospitalizationsExclusion of patientsStudies of vaccine effectivenessAcute respiratory illnessTest-negative studySentinel Surveillance NetworkEstimates of VEInfluenza VEInfluenza-associatedVE controlsReal-world analysisSyncytial virusVE estimatesOverall VEVE analysisPatientsInfluenzaRespiratory illnessVaccine-preventableInterim Estimates of 2023–24 Seasonal Influenza Vaccine Effectiveness — United States
Frutos A, Price A, Harker E, Reeves E, Ahmad H, Murugan V, Martin E, House S, Saade E, Zimmerman R, Gaglani M, Wernli K, Walter E, Michaels M, Staat M, Weinberg G, Selvarangan R, Boom J, Klein E, Halasa N, Ginde A, Gibbs K, Zhu Y, Self W, Tartof S, Klein N, Dascomb K, DeSilva M, Weber Z, Yang D, Ball S, Surie D, DeCuir J, Dawood F, Moline H, Toepfer A, Clopper B, Link-Gelles R, Payne A, Chung J, Flannery B, Lewis N, Olson S, Adams K, Tenforde M, Garg S, Grohskopf L, Reed C, Ellington S, Collaborators C, Collaborators C, Lauring A, Arndorfer J, Bride D, Peltan I, Mohr N, Hager D, Prekker M, Mohamed A, Johnson N, Steingrub J, Khan A, Busse L, Duggal A, Wilson J, Qadir N, Mallow C, Kwon J, Exline M, Shapiro N, Columbus C, Vaughan I, Mosier J, Safdar B, Harris E, Chappell J, Stewart L, Swan S, Piedra P, Sahni L, Englund J, Zerr D, Hickey R, Williams J, Rohlfs C, Schlaudecker E, Dosdos D, Moffatt M, Schuster J, Weltmer K, Szilagyi P, Curley T, Mills J, Faryar K, Salata R, Geffel K, Nowalk M, Murthy K, Rose S, Smith M, Wickersham B, Williamson B, Bontrager N, Williams O, Kramer J, Nordstrom L, Monto A, Vaughn I, Dickerson M, McLean C, Noble E, Ray C, Sumner K, Essien I, Fletcher L, Heaton P, Kane S, McEvoy C, Thapa S, Vazquez-Benitez G, Bezi C, Contreras R, Davis G, Lewin B, Mahale P, Patrick R, Qian L, Rayens E, Reyes I, Ryan D, Salas S, Sy L, Yeh M, Zeng X, Fireman B, Goddard K, Hansen J, Jacobson K, Timbol J, Zerbo O, Dunne M, Zhuang Y. Interim Estimates of 2023–24 Seasonal Influenza Vaccine Effectiveness — United States. MMWR Morbidity And Mortality Weekly Report 2024, 73: 168-174. PMID: 38421935, PMCID: PMC10907036, DOI: 10.15585/mmwr.mm7308a3.Peer-Reviewed Original ResearchConceptsVaccine effectivenessInfluenza vaccineInfluenza virus infectionInfluenza-associated hospitalizationsAnnual influenza vaccinationSeasonal influenza vaccineTest-negative case-control study designCase-control study designOutpatient visitsInfluenza VEInfluenza BInfluenza seasonInfluenza APediatric patientsInfluenzaVirus infectionOutpatient settingMonthsVaccinePatientsStudy designHospitalAdultsVisitsUnited States